普华赛尔

Puhua Saier is a clinical-stage biotechnology company based in Tianjin, China, specializing in the development of innovative cell therapies for oncology and regenerative medicine. The company focuses on chimeric antigen receptor (CAR) technologies, including CAR-T and CAR-NK cells, to treat hematological malignancies and solid tumors. Their pipeline features several candidates targeting CD19 and BCMA, with lead programs currently undergoing clinical evaluation. In addition to immunotherapy, Puhua Saier explores stem cell-based therapies for various degenerative conditions. The company leverages its proprietary cell engineering platforms to improve the efficacy and accessibility of advanced biologics.